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Introduction
Spontaneous intracerebral haemorrhage
(ICH) that isapparently unrelated to trauma
or an underlying vascular, neoplastic, or
coagulopathic cause has incurred the same
global burden over the past quarter of a
century [1,2]. During the last decade,
spontaneous ICH accounted for ,10% of
strokes in high income countries and ,20%
of strokes in low and middle income
countries, where the one month case
fatalities were 25%–35% and 30%–48%,
respectively [3].
The incidence of ICH is higher in Asians
[2], and the major risk factors for spontane-
ous ICH without an identified cause (so-
called primary ICH) are male gender,
systemic arterial hypertension, excessive
alcohol consumption, increasing age, smok-
ing, and diabetes mellitus [4]. However, over
the past quarter of a century, the incidence of
primary ICH associated with pre-stroke
hypertension seems to have declined, where-
as there seems to have been an increase
associated with antithrombotic use and
presumed cerebral amyloid angiopathy in
those aged $75 years [1]. Whilst primary
prevention with antihypertensive medication
is probably the most effective strategy to
reduce the burden of ICH, could the
management of ICH influence outcome?
The outcome after primary ICH seems to
be worse than after a bleed secondary to an
arteriovenous malformation [5], which justi-
fies thorough investigation for all patients
(Table 1). However, there is a shortage of
evidence and lack of consensus about who,
when, and how to further investigate for a
cause underlying ICH [6]. There appears to
be a modest association between ICH deep in
the brain and hypertension, and between
ICH in the lobes of the brain and cerebral
amyloid angiopathy [7,8], but these associa-
tions by no means rule out the need for
further investigation of patients who are likely
to survive and benefit from the identification
of a treatable underlying cause (Table 1) [9].
Apart from identifying and treating under-
l y i n gc a u s e so fI C H ,t h i sr e v i e wf o c u s e so n
other strategies to improve outcome, bearing
in mind the pathophysiological mechanisms
underlying clinical deterioration after ICH.
We go on to address the treatments for
primary ICH that are supported by rando-
mised controlled trials (RCTs) and those that
are not, and discuss which interventions
appear to be the most promising in ongoing
and future RCTs.
Pathophysiology of Acute ICH
In humans, known pathophysiological
mechanisms underlying further clinical dete-
rioration soon after ICH include hydroceph-
alus, intraventricular extension of ICH, and
recurrent ICH [10]; pathological and radio-
logical studies have illuminated additional
mechanisms (Figure 1). Human studies
performing brain computed tomography
within two time windows after ICH onset
have documented haematoma expansion
(Figure 2)—either due to growth of the
original haemorrhage or re-bleeding [11–
21]—that is associated with poor outcome
[12,16,18,22]. Imaging studies have demon-
strated peri-haematomal hypoperfusion with-
in the first week of ICH onset [23,24], but
not an ‘‘ischaemic penumbra’’ [25,26].
However, there is evidence of a compensa-
tory reduction in the metabolic rate, or
a ‘‘metabolic penumbra’’, around ICH
[25,26], as well as peri-haematomal hyper-
glycolysis (possibly due to inflammation,
excitotoxicity, spreading depression, or sei-
zures) [27]. Perihaematomal oedema ap-
pears to be vasogenic (plasma-derived) [28],
its volume may increase within 24 hours of
ICH onset and peak within 14 days [29–31],
and it may be caused or exacerbated by
thrombin and activated platelets [32,33].
Animal models support the contributions
to peri-haematomal oedema made by clot
retraction, hydrostatic pressure, enhanced
thrombin production, increased blood–
brain barrier permeability, and products of
erythrocyte lysis (such as haeme oxygenase-
mediated liberation of iron from haeme
rings) [32,34–37]. ICH in animal models
seems to trigger humoral and cellular
inflammatory responses: the consequent
migration and recruitment of neutrophils
and activation of native microglia results in
oxidative stress and neuronal necrosis
[38,39], cytokines such as tumour necrosis
factoraand interleukin 1-bleadtoapoptosis
[40,41], complement activation causes
erythrocyte lysis [42], and matrix metallo-
proteinases may result in oedema, necrosis,
and blood–brain barrier disruption [43].
A better understanding of the patho-
physiology of ICH could emerge if the
decline in human autopsy rates reverses
[44], and if animal models of ICH better
represent humanICH[45]. Rodent models
of ICH involve either stereotactic intrapa-
renchymal infusion of autologous whole
blood (which may cause simultaneous
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rhage [46]), or injection of proteolytic
bacterial collagenase (which incites a vig-
orous immune response in excess of that
seen in humans [46]), after which very few
animals die, which is quite unlike sponta-
neous ICH in humans [2].
Treatments Shown to Be
Beneficial in Humans, Either in a
Meta-Analysis of RCTs or in a
Single Large RCT
A Cochrane meta-analysis of 31 RCTs
involving 6,936 participants showed that
organised inpatient care in stroke units
benefits patients with stroke (whether
ischaemic or due to ICH) by reducing the
odds of death or dependency by 18% [47].
Large observational studies corroborate
these findings in patients with ICH
[48,49]. Which aspects of organized stroke
care, either individually or together, im-
prove outcome in patients with ICH
remain to be determined. One small, non-
randomised, observational analysis, which
was adjusted for some of the known
influences on ICH prognosis, found surviv-
al after ICH to be better when managed in
neuro-intensive care units compared to
general intensive care units [50]: RCTs of
someof the interventions used in the ‘‘black
box’’ of neuro-intensive care (such as acute
blood pressure lowering) are underway (see
below). Furthermore, the benefits of stan-
dard care can be inferred from the effects
on clinical outcome of do-not-resuscitate
orders in a case-mix adjusted multi-hospital
observational study [51], and withdrawal of
care in a multivariable analysis at a single
hospital [52].
A Cochrane meta-analysis of ten RCTs
involving 2,059 participants found a reduc-
tion in death or dependence from the
neurosurgical evacuation of spontaneous
supratentorial ICH (odds ratio [OR] 0.71,
95% confidence interval [CI] 0.58 to 0.88)
[53]. However, most of the RCTs included
in this meta-analysis were of modest quality,
their methods differed, and the largest RCT
(Surgical Trial in Intracerebral Hemor-
rhage [STICH]) found no difference be-
tween early surgery or initial conservative
management [54]. A sub-group with lobar
ICH within 1 cm of the cortical surface
appeared to benefit from surgery in
STICH, so the STICH II RCT (ISRCTN
22153967) is evaluating early ICH evacua-
tion in this sub-group of patients.
Secondary prevention with anti-hyper-
tensive drugs reduced the risk of vascular
events after stroke in the PROGRESS
RCT; amongst the subset of 611 partici-
pants with ICH, the risk of subsequent
stroke was halved by a perindopril-based
blood pressure lowering regimen [55].
Treatments Neither Shown to
be Beneficial to Humans in a
Meta-Analysis of RCTs, Nor in a
Single Large RCT
Haemostatic drugs are a biologically
plausible intervention to improve outcome
after ICH by limiting the early growth of
spontaneous ICH (Figure 2). Despite the
ability of recombinant activated factor VII
(rFVIIa) to curtail early haematoma
growth by 4–6 ml, a Cochrane meta-
Summary
Intracerebral haemorrhage (ICH) accounts for ,10% and ,20% of strokes in high
and low-middle income countries, respectively, but ICH incidence and case
fatality do not appear to be declining. Evidence supports organised stroke unit
care and secondary prevention with blood pressure lowering after ICH. Ongoing
randomised controlled trials of treatments that are either intended to limit early
ICH growth, reduce perihaematomal oedema, or modify other key pathophys-
iological mechanisms underlying deterioration after acute ICH, offer hope for
future improvements in outcome.
Table 1. Investigations into Common Causes of Secondary Intracerebral
Haemorrhage (ICH).
Investigation Common Causes Identified by the Investigation
Further history from patient and others Undisclosed trauma, drug use
Routine laboratory tests
a Vasculitis
Liver cirrhosis
Neoplasm (secondary)
Infective endocarditis
Coagulation studies Warfarin
Von Willebrand disease
Vitamin K deficiency
Factor VIII, IX, XIII deficiency
Blood cultures Infective endocarditis
Toxicology Cocaine
Amphetamines
Human chorionic gonadotrophin (b-hCG) Pregnancy
Cerebrospinal fluid analysis
b Vasculitis
CT, CT angiography, CT venography Neoplasm (primary or secondary)
Intracranial arterial aneurysm
Intracranial arteriovenous malformation
Intracranial venous thrombosis
MRI, MR angiography, MR venography Cavernous malformation
Intracranial arterial aneurysm
Intracranial arteriovenous malformation
Haemorrhagic transformation of a cerebral infarction
Neoplasm (primary or secondary)
Cerebral catheter angiography Intracranial arterial aneurysm
Intracranial arteriovenous malformation
Dural arteriovenous fistula
Vasculitis
Neuroradiologist review of brain imaging All causes whose identification depends on brain imaging
aFull blood count, electrolytes, creatinine, urea, liver function tests, inflammatory markers (ESR/CRP),
electrocardiogram, chest radiograph.
bConsider the risk of transtentorial herniation before undertaking.
CT, computed tomography; MRI, magnetic resonance imaging.
doi:10.1371/journal.pmed.1000353.t001
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participants found that this surrogate
outcome did not translate into any net
clinical benefit (risk ratio of death or
dependence [modified Rankin Scale score
4 to 6] at 90 days=0.91 [95% CI 0.72 to
1.15]). This reduction in ICH growth may
have been too small to improve clinical
outcome, its benefit may have been offset
by the thrombo-embolic adverse effects of
rFVIIa, or the RCTs might have been
unable to detect a small benefit of rFVIIa
because of insufficient precision or some
methodological weaknesses [56]. Other
haemostatic drugs including antifibrinolyt-
ic agents seem to be worth testing in future
RCTs.
Similarly, early blood pressure lowering
might improve outcome after ICH by
limiting the early growth of spontaneous
ICH, but there has been a shortage of
evidence supporting this intervention,
unsurprisingly leading to differences be-
tween ICH guidelines [9,57]. The Inten-
sive Blood Pressure Reduction in Acute
Cerebral Haemorrhage Trial (INTER-
ACT) randomized 404 patients presenting
within 6 hours of onset to a systolic blood
pressure target of #140 mmHg achieved
within 1 hour and continued for 7 days,
versus the American Heart Association
guideline’s target [9,58]. There was a
non-significant reduction in ICH growth
by 1–2 ml, and no effect on clinical
Figure 1. Selected pathophysiological mechanisms that have been identified in
humans after acute, spontaneous intracerebral haemorrhage. Shapes are approximate
illustrations of when pathophysiological mechanisms are at their peak and their known durations.
Uncertainties about the duration and intensity of mechanisms are indicated by dashed lines.
doi:10.1371/journal.pmed.1000353.g001
Figure 2. Summary of selected radiological studies of spontaneous intracerebral haemorrhage growth. Studies are organised in ascending
order of the duration of the time window of the first computed tomogram. Manual calculations of haematoma volume used the ABC/2 method. We
excluded data on patients taking anticoagulant drugs in these studies, and excluded studies from which data could not be extracted [77,78], studies that
incorporated patients already included in the summary above [79,80], or studies in which interventions may have influenced haematoma growth [58,81].
doi:10.1371/journal.pmed.1000353.g002
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aging for the large, ongoing Intensive
Blood Pressure Reduction in Acute Cere-
bral Haemorrhage Trial (INTERACT-2;
ISRCTN 73916115).
Attenuating peri-haematomal oedema
might improve outcome after ICH
(Figure 1), but meta-analyses have dem-
onstrated neither benefit nor harm from
dexamethasone (five RCTs involving 206
participants) [59], glycerol (two RCTs
involving 224 participants) [60], and
mannitol (two RCTs involving 149 partic-
ipants) [61]. Neuroprotection, too, has
caused neither benefit nor harm after
acute ICH with the anti-oxidant free-
radical scavenger NXY-059 (one RCT
involving 607 participants) [62] or the
glycine antagonist gavestinel (one RCT
involving 571 participants) [63].
Future Directions
Attenuation of Haematoma Growth
The major treatment target of ongoing
RCTs is haematoma growth, because ICH
size and growth are determinants of out-
come [12,16,18,22]. So far, the attenuation
of early ICH growth seen with the haemo-
static agent rFVIIa [56] or intensive acute
blood pressure lowering [58,64] has not
improved clinical outcome in the RCTs
performed. However, this biologically plau-
sible mechanism for improving outcome is
worthy of further research in RCTs that
are large enough to detect small clinical
benefits, such as the ongoing RCTs of acute
blood pressure lowering (including INTER-
ACT-2, the Efficacyof Nitric Oxide in Stroke
Trial [ENOS; ISRCTN 99414122], Antihy-
pertensive Treatment of Acute Cerebral
Hemorrhage II [ATACH-II; ISRCTN
R01-NS044976], and the Scandinavian
Candesartan Acute Stroke Trial [SCAST;
ISRCTN 13643354]). RCTs of alternative
approaches to improve outcome after prima-
ry ICH by limiting haematoma expansion
include rFVIIa in sub-groups of patients
whose haematomas are more likely to grow
(The Spot Sign for Predicting and Treating
ICH Growth Study [STOP-IT; NCT-
00810888]), or testing the effectiveness of
antifibrinolytic drugs such as the lysine
analogue tranexamic acid, which seems to
have attenuated ICH growth in two non-
randomised studies [65,66].
The greater risk of haematoma expansion
and death after ICH associated with warfarin
[67] and the contemporary increase in the
incidence of primary ICH associated with all
antithrombotic drugs [1] make RCTs of the
management of antithrombotic-associated
ICH a priority. Whilst stopping warfarin
after ICH is common sense, and intravenous
vitamin K administration is standard prac-
tice, there is a shortage of evidence about how
else to treat anticoagulant-associated ICH
[68], so RCTs comparing prothrombin
complex concentrate with fresh frozen plas-
ma in this context are ongoing (International
Normalized Ratio (INR) Normalization in
Coumadin Associated Intracerebral Haem-
orrhage [INCH; NCT00928915] and Effi-
cacy and Safety of BERIPLEX P/N Com-
pared with Plasma in Patients with Acute
Major Bleeding Caused by Anticoagulant
Therapy [NCT00708435]), as are studies of
rFVIIa. The finding that mortality is higher
forpatients who were on antiplatelet agents at
the time of ICH compared to those who were
not [69] has led to an ongoing RCT of
platelet transfusion to limit ICH growth and
improve outcome after ICH associated with
antiplatelet drugs (Platelet Transfusion in
Cerebral Haemorrhage [PATCH; http://
www.strokecenter.org/trials/TrialDetail.
aspx?tid=730).
Other Approaches
Firstly, targeting other potentially treat-
able determinants of poor outcome after
ICH may be fruitful. Intraventricular exten-
sion of ICH is one such mechanism [10],
and there are two RCTs of ventricular
drainage combined with intraventricular
recombinant tissue plasminogen activator
(Dutch Intraventricular Thrombolysis after
Cerebral Haemorrhage Study [DITCH;
ISRCTN 19105863] and Clot Lysis: Eval-
uation Acceleration of Resolution of IVH
[CLEAR-IVH; NCT00650858]).
Secondly, just as the PATCH RCT is a
response to the apparent rise in incidence
of antiplatelet-associated ICH, the appar-
ent rise in the incidence of lobar ICH
that may be caused by cerebral amyloid
angiopathy merits consideration of treat-
ments that might reduce amyloid deposi-
tion [1]. Tramiprosate is a synthetic
compound that competes with glycosami-
noglycans for binding to b-amyloid pep-
tide, reducing amyloid fibril formation and
deposition, and demonstrated a good
safety profile in a phase II study [70].
Amyloid-depleting agents, which have
shown remarkable effects in Alzheimer’s
disease [71], are an alternative approach
and may be preferable to amyloid-b
immunisation, which can induce an im-
mune-mediated encephalomyelitis [72].
Lastly, treatments that have proven
beneficial in animal models might translate
from the bench to the bedside, although
there are concerns about the rodent ICH
models used and the methodological qual-
ity of animal experiments [45,46,73]. One
such example is deferoxamine (an iron-
chelating agent that crosses the blood–
brain barrier, and has been associated with
a reduction in brain oedema, neurological
deficits, and biochemical markers of oxida-
tive damage in animals) [74,75], which has
led to the Dose Finding and Safety study of
Deferoxamine in Patients with Brain Hem-
orrhage (DFO in ICH; NCT00598572).
Conclusions
The incidence and risk of dying from ICH
seem not to have changed in recent decades,
whilst the incidence of ischaemic stroke has
declined [2,3]. In contrast to the advances in
the treatment of ischaemic stroke, stroke unit
care and secondary prevention with blood
pressure reduction are the only interventions
for patients with stroke due to ICH that are
based on robust evidence [47,55]. However,
insights gleaned from radiological and path-
ological investigations of the cause and
pathophysiology of ICH, and the relentless
pursuit of potential treatments in ongoing
RCTs, are all cause for optimism [76].
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